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Cancer survival rates decrease in the presence of disseminated disease. However, there are few therapies that are effective at
eliminating the primary tumour while providing control of distant stage disease. Photodynamic therapy (PDT) is an FDA-approved
modality that rapidly eliminates local tumours, resulting in cure of early disease and palliation of advanced disease. Numerous pre-
clinical studies have shown that local PDT treatment of tumours enhances anti-tumour immunity. We hypothesised that enhancement
of a systemic anti-tumour immune response might control the growth of tumours present outside the treatment field. To test this
hypothesis we delivered PDT to subcutaneous (s.c.) tumours of mice bearing both s.c. and lung tumours and monitored the growth of
the untreated lung tumours. Our results demonstrate that PDT of murine tumours provided durable inhibition of the growth of
untreated lung tumours. The inhibition of the growth of tumours outside the treatment field was tumour-specific and dependent on
the presence of CD8
þ T cells. This inhibition was accompanied by an increase in splenic anti-tumour cytolytic activity and by an
increase in CD8
þ T cell infiltration into untreated tumours. Local PDT treatment led to enhanced anti-tumour immune memory that
was evident 40 days after tumour treatment and was independent of CD4
þ T cells. CD8
þ T cell control of the growth of lung
tumours present outside the treatment field following PDT was dependent upon the presence of natural killer (NK) cells. These results
suggest that local PDT treatment of tumours lead to induction of an anti-tumour immune response capable of controlling the growth
of tumours outside the treatment field and indicate that this modality has potential in the treatment of distant stage disease.
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Cancer survival rates decrease significantly in patients with
distant-stage disease; for example, the 5-year relative survival rate
is 98% for breast cancer patients with localised disease and only
26% for those with distant-stage disease (Ries et al, 2006). There
are few effective treatments for distant-stage disease and thus there
is an increased interest in therapies that result in both the
elimination of primary tumours and the systemic activation of
anti-tumour immune responses. Photodynamic therapy (PDT) is
an anti-tumour modality that causes tumour destruction through
generation of reactive oxygen species (ROS). ROS are produced on
illumination of tumours with a specific wavelength of light
following administration of a photoreactive drug or photosensi-
tiser. PDT is approved for clinical use in a number of countries,
including the United States, for the elimination of early stage
malignancies and the palliation of symptoms and the reduction of
obstruction in patients with late-stage tumours (Dougherty, 2002;
Brown et al, 2004).
Photodynamic therapy was initially considered to be primarily a
local treatment that caused direct tumour destruction via ROS and
indirect tumour damage through vascular damage and induction
of inflammation (Oleinick and Evans, 1998; Henderson and
Gollnick, 2003). However, several studies have indicated that local
PDT treatment of tumours can result in wide-spread effects
including systemic neutrophilia (Cecic et al, 2001), induction of
acute-phase proteins (Cecic et al, 2001; Gollnick et al, 2003),
increased circulating levels of complement proteins (Cecic et al,
2006) and systemic release of pro-inflammatory cytokines (Nseyo
et al, 1990; Ziolkowski et al, 1996; de Vree et al, 1997; Cecic and
Korbelik, 2002; Gollnick et al, 2003; Yom et al, 2003), all of which
indicate the presence of a systemic inflammatory response.
Subsequent studies showed that local PDT treatment of murine
tumours results in the induction of anti-tumour immunity and
resistance to subsequent tumour challenge (reviewed in Canti et al,
2002; Castano et al, 2006).
The ability of PDT to induce systemic anti-tumour immunity led
us to hypothesise that PDT treatment may have an effect on
established tumours present outside the local treatment field. To
address this hypothesis the effect of PDT treatment of s.c. tumours
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son the growth of established lung tumours in immuno-competent
mice bearing concomitant s.c. and lung tumours was examined.
Previous studies that have examined the effect of local PDT on
distant tumours have done so in the absence of an intact immune
system (Schreiber et al, 2002), were unable to detect control of
distant disease (van Duijnhoven et al, 2003), performed PDT
before establishment of distant tumours (Momma et al, 1998), or
have not discerned a mechanism by which PDT inhibits the growth
of tumours outside the treatment field (Gomer et al, 1987; Blank
et al, 2001; Castano et al, 2003). In the current study, we
demonstrate that control of the growth of tumours present outside
the treatment field is dependent upon an intact immune system, is
mediated by CD8
þ T cells and is accompanied by induction of
anti-tumour immune memory responses.
It is generally accepted that the generation and maintenance of
effective memory CD8
þ T cells is dependent upon the presence of
CD4
þ T cells (reviewed in Castellino and Germain, 2006),
although there are conflicting reports (Marzo et al, 2004; Wang
et al, 2004). We have examined the requirement for CD4
þ T cells
in the generation of anti-tumour immune memory following PDT.
In this report, we show that in the absence of CD4
þ T cells local
PDT treatment is able to stimulate the generation of effective and
persistent CD8
þ T cell-mediated immune memory responses and
that PDT induction of CD8
þ T cell-dependent control of distant
tumour growth requires natural killer (NK) cells.
These studies demonstrate that PDT induced anti-tumour
immunity can be independent of CD4
þ T cells and suggest that
PDT may be beneficial in the control of distant disease.
MATERIALS AND METHODS
Animal and tumour models
Eight- to twelve-week-old pathogen-free BALB/cJ, CNCr. 129P2-
Cd40
tm1Kik/J (CD40
 / ) mice (Jackson Labs, Bar Harbour, ME,
USA) or SCID mice (Roswell Park Cancer Institute) were injected
s.c. with 3 10
5 EMT6 (murine mammary carcinoma) tumour
cells/mouse on the right shoulder (Henderson et al, 1985). In
experiments examining the effect of PDT on lung tumour growth
the mice were injected with 1 10
4 EMT6 tumour cells i.v. to
establish tumours in the lungs. The RPCI Institutional Animal Care
and Use Committee (IACUC) approved all procedures carried out
in this study and the procedures used were in compliance with the
UKCCCR guidelines.
EMT6 cells were grown in DMEM, supplemented with 15% FBS
and antibiotics (all from GIBCO-BRL, Grand Island, NY, USA);
Colon 26 cells were grown in RPMI-1640, supplemented with 10%
FBS and antibiotics. All cells were cultured in a humidified
atmosphere of 5% CO2 in air at 371C.
PDT treatment
At day 6 after s.c. tumour inoculation or when the tumours had
reached 5 5mm, the mice were injected i.v. with Photofrin
s
(porfimer sodium; QLT Inc., Vancouver, British Columbia) at a
dose of 5mgkg
 1. After 18 to 24h, the primary s.c. tumours were
exposed to 630nm light delivered by an argon laser-pumped dye
laser (Spectra Physics, Mountain View, CA, USA) at a total light
fluence of 135Jcm
 2 at a fluence rate of 75mWcm
 2. Control
groups included mice that were either treated with PDT on a 1cm
3
spot of skin opposite the s.c. tumour, had their s.c. tumour
surgically removed, were treated with drug or light alone, or
received no treatment.
Assessment of lung tumours
Mice bearing EMT6 lung tumours were euthanised 10–60 days
post-PDT and lung tumours were assessed as described earlier
(Pulaski et al, 1996). Briefly, 1ml of 15% India ink (diluted in
phosphate-buffered saline) was injected via an incision in the
trachea. Normal lung tissue absorbs the ink while lung lesions
remained white. The lungs were then removed from the rib cage
and placed in Fekete’s fixative (61% ethanol, 3.2% formaldehyde,
4.1% acetic acid). After a minimum of 2 days in the fixative, lung
tumours were counted under a dissecting microscope.
Cytolytic assay
Spleens were harvested from experimental and control mice 10
days post-treatment, single cell suspensions were generated and
depleted of red blood cells. Cells were combined with
51Cr-labeled
EMT6 or Colon 26 tumour cell and incubated at 371Ci na
humidified atmosphere containing 5% CO2 for 4h. Percent specific
lysis was calculated as follows:
100 ½ðcpmexperimental   cpmbkgdÞ ð cpmspontaneous   cpmbkgdÞ =
½ðcpmmaximal   cpmbkgdÞ ð cpmspontaneous   cpmbkgdÞ 
Flow cytometry
The cell populations present in EMT6 tumours were characterised
by fluorescence-activated cell sorting (FACS) analysis, using panels
of monoclonal antibodies (MAbs) to detect specific cell surface
antigens as described previously (Gollnick et al, 1997). Briefly,
tumours were disaggregated in 25ml of HBSS containing 50mg of
collagenase, type II (Worthington Biochemical Corp., Freehold, NJ,
USA), and 500mg of BSA. MAbs conjugated directly with
fluorescein or phycoerythrin or biotin was used to quantify cells
expressing CD4
þ and CD8
þ T-cell antigens (PharMingen, San
Diego, CA, USA). Appropriate immunoglobulin isotypes were used
as controls. In cases where biotinylated antibodies were used,
streptavidin-cychrome (PharMingen) was added as a detection
reagent.
For flow cytometric analysis a two-laser FACStar Plus (Becton-
Dickinson, San Jose, CA, USA) flow cytometer was used, operating
in the ultraviolet (UV) and at 488nm. Four colours and light
scattering properties could be resolved employing 420/20, 530/30,
and 575/30nm band-pass filters and a 640nm long-pass filter. Data
were acquired from 5000cells, stored in collateral list mode, and
analysed using the WinList processing programme (Verity Soft-
ware House Inc., Topsham, ME, USA). Results are presented as the
average percentage of total cells; a total of three animals were
analysed for each treatment group.
Depletion of immune cells
GK1.5 and 53-6.72 rat hybridomas (ATCC, Rockville, MD, USA)
were used to generate anti-CD4 and anti-CD8 antibodies,
respectively. Briefly, the hybridomas were used to produce ascites
in BALB/cJ mice. The ascites were subjected to sodium ammonium
sulphate precipitation to obtain CD4 and CD8-specific IgG. Eight-
to twelve-week-old BALB/cJ mice were injected with 100mg of the
purified antibodies, a combination of the two antibodies or isotype
control (Rat IgG) antibodies (Caltag, San Francisco, CA, USA) for 3
consecutive days, then every other day through the duration of the
experiments. After 6 days of depletion, mice were inoculated with
s.c. and lung tumours and subjected to PDT as described above.
NK cells were depleted by two methods, treatment with anti-asialo-
GM1 antibody or treatment with the monoclonal antibody TM-b1,
which is specific for the IL-2 receptor b chain (Tanaka et al, 1993).
Mice were treated with 50ml of anti-asialo-GM1 antibody (Wako
Chemicals, Richmond, VA, USA) starting on day 1 and continuing
every 5 days for the duration of the experiment. TM-b1
(100mgmouse
 1) was injected into SCID mice 7 days before
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sinjection with EMT6 tumour cells. Cell specific depletion was
confirmed by flow cytometry at the time of lung harvest.
Isolation of T-cell subsets
Single-cell suspensions of spleens from naı ¨ve mice were prepared
and red blood cells were lysed. Monocytes were eliminated by
plastic adherence. CD8
þ and CD4
þ T cells were isolated by
negative selection using MACs beads (Miltenyi Biotech, Auburn,
CA, USA) according to the manufacturer’s instructions. CD8
þ T
cells were recovered at a 490% purity.
Reconstitution of SCID mice
Splenocytes harvested at various times following treatment from
treated and control mice were depleted of CD8 and/or CD4
expressing T cells (Miltenyi Biotech) and injected i.v. into SCID
mice (10
7cellsmouse
 1). Two days after reconstitution mice were
challenged by injection of 10
4 EMT6 cells i.v. The presence of lung
tumours was assessed 10 days later. For analysis of immune
memory responses, purified CD8
þ T cells (5 10
6cellsmouse
 1)
were injected into SCID mice i.v. Two days after immune cell
transfer, the mice were inoculated with EMT6 tumour cells s.c.; 7
days later, tumour bearing recipient mice were treated with PDT
and allowed to rest for 40 days. Mice were then challenged with
EMT6 tumour cells (10
4cellsmouse
 1) i.v. and the presence of
lung tumours was assessed 10 days after tumour challenge.
Statistical analyses
Statistical analysis was performed using a non-paired Student’s
t-test. Significance was defined as Po0.05.
RESULTS
Local PDT results in systemic control of distant tumours
A number of studies have indicated that PDT enhances anti-
tumour immune responses (reviewed in Canti et al, 2002; Castano
et al, 2006) and we hypothesised that the enhanced anti-tumour
immunity could lead to control of tumours present outside the
PDT treatment site. To determine the existence and extent of such
a mechanism, s.c. tumours of mice bearing both s.c. tumours and
lung EMT6 tumours were treated with PDT. This led to 90–100%
ablation of the s.c. tumour (data not shown) and significantly
reduced the number of lung tumours present 10 days post-
treatment (PDT, Figure 1A) when compared to the number of lung
tumour present in animals whose s.c. tumours were treated with
light alone (Control, Figure 1A; Po0.003) or whose s.c. tumors
were surgically removed (SR; Po0.008). In contrast, there was no
significant difference between the number of lung tumours present
in mice whose s.c. tumours were treated with light alone or
surgically removed 18–24h post-Photofrin administration
(P40.56). The inhibition of lung tumour growth observed
following PDT was durable; 11 out of 17 mice (62.5%) exhibited
no lung tumours 10 days post-PDT, while 12 out of 14 mice (86%)
exhibited no lung tumours at 35 days post-PDT and 100% of mice
(10 out of 10 mice) were tumour-free at 60 days post-PDT.
We considered that the observed control of lung tumours might
have been due to the activation of Photofrin by scattered light from
the treatment of the s.c. tumours. To test for this possibility,
animals bearing both s.c. and lung tumours were given Photofrin
and treated with light 18–24h later on the shoulder contralateral
to the s.c. tumour (Figure 1A; PDT/skin). This treatment did not
result in a significant difference in the number of lung tumours
when compared to the Control (P40.13). These results support the
conclusion that local PDT treatment of s.c. tumours results in a
systemic response that leads to control of the growth of tumours
outside the treatment field. The data also suggest that treatment of
tumour tissue is required for the observed reduction in distant
lung tumours.
To demonstrate whether PDT resulted in enhanced cytolytic
activity against tumour cells, spleen cells were harvested 10 days
post-treatment from animals whose tumours were surgically
removed or were treated with PDT and used as effector cells in
cytotoxicity assays. As can be seen in Figure 1B, PDT-induced
splenic cytolytic activity, which was not observed in naı ¨ve animals
and was significantly greater than that induced in animals whose
tumours were surgically removed (Po0.03 at all effector-to-target
ratios). Minimal, but significantly greater, cytolytic activity was
seen in animals whose tumours were surgically removed as
compared to naı ¨ve animals at the highest effector-to-target ratio
(Po0.005). PDT-treated animals did not exhibit significant splenic
cytolytic activity against major histocompatibility complex (MHC)
matched Colon 26 tumour cells (P40.5 when compared to
cytolytic activity present in naı ¨ve animals).
To ascertain whether in vivo control of tumours present outside
the treatment field was also tumour-specific, the s.c. tumours of
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Figure 1 Control of distant disease by PDT is immune cell mediated.
(A) S.c. tumours present on BALB/cJ mice bearing s.c. and lung tumours
were either treated with light only (Control, n¼5), surgically removed 18–
24h post-Photofrin administration (SR, n¼16), or received PDT (n¼16).
The PDT/skin column (n¼6) represents results from mice bearing both s.c.
and lung tumours that were treated with Photofrin and had a 1cm
3 area of
skin on the non-tumour bearing shoulder illuminated with 630nm light. The
average number of lung tumours was determined as described in Materials
and Methods; error bars represent s.e.m. Significance was calculated by
Student’s t-test. (B) Spleen cells isolated from naı ¨ve animals (K) or from
mice whose s.c. tumours were surgically removed (’) were mixed with
51Cr-labeled EMT6 target cells at various effector-to-target cell ratios.
Spleen cells from mice whose tumours were PDT treated were mixed with
either
51Cr-labeled EMT6 (&) or Colon 26 (m) target cells. Effector and
target cells were incubated for 4h and the percent specific lysis was
determined as described in Materials and Methods. Spleen cells from a
minimum of six mice were used for each point; error bars represent s.e.m.
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were treated with Photofrin-PDT. PDT of the s.c. Colon 26 tumours
had no effect on the growth of EMT6 tumours present in the lung
(100.6734.2 tumours per lung; P40.22 when compared to the
number of lung tumours present in animals whose s.c. EMT6
tumours were treated with PDT).
We next established whether the effect of PDT on tumours
outside the treatment field was dependent upon adaptive immune
cells by examining the ability of PDT to control the growth of
tumours present outside the treatment field in immuno-compro-
mised SCID mice, which lack T and B cells. The s.c. tumours of
SCID mice bearing s.c. and lung tumours were treated with PDT
and the number of EMT6 lung tumours was assessed (Figure 2).
The effect of PDT on the inhibition of EMT6 lung tumour growth
was significantly reduced in SCID mice (Po0.001 when compared
to the number of lung tumours present following PDT in BALB/cJ
mice).
The combined results of these experiments indicate that PDT is
able to control the growth of tumours outside the treatment field in
a tumour-specific manner, that PDT enhances tumour-specific
cytotoxicity and that control of tumours outside the treatment field
by PDT is dependent upon the presence of adaptive immune cells.
CD8
þ T cells mediate inhibition of distant tumour growth
post-PDT
The results presented in Figure 2 suggest that the ability of local
PDT treatment to control the growth of tumours outside the
treatment field is mediated by adaptive immune cells as control
was lost in immunocompromised mice. To determine which
adaptive immune cells were involved in systemic control of
tumours following local PDT, BALB/cJ mice were treated with
monoclonal antibodies specific for CD4, CD8 or both antibodies
together to deplete T-cell subsets before tumour inoculation. The
depletion status was maintained for the duration of the experiment
as shown in Figure 3A. Depletion of CD4
þ cells had no effect on
the ability of PDT to control tumours present outside the
treatment field (Figure 3B; P40.35 when compared to animals
treated with isotype control antibodies). In contrast, depletion of
CD8
þ cells or the combination of CD4
þ and CD8
þ cells abolished
the ability of PDT to control distant lung tumour growth
(Po0.0004 and Po0.0001, respectively, when compared to animals
treated with isotype control antibodies). There was no significant
difference between the ability of mice depleted of CD8
þ cells
and those depleted of both CD4
þ and CD8
þ cells to control
distant lung tumour growth. Furthermore, at the time of lung
tumour growth assessment all s.c. tumours were regrowing in the
PDT-treated mice depleted of CD8
þ cells and those depleted of
both CD8
þ and CD4
þ cells; however, the growth of the s.c.
tumours was not inhibited in the PDT-treated mice depleted of
CD4
þ cells.
To confirm the importance of CD8
þ T cells in control of distant
disease, SCID mice were reconstituted by adoptive transfer of
lymphocytes isolated from EMT6 tumour bearing animals 3 days
post-PDT treatment or surgical removal of s.c. tumours. Lympho-
cytes were treated with either isotype control or depleted of either
CD4
þ or CD8
þ T cells before transfer into SCID mice. Two days
after the adoptive transfer, recipient animals were challenged with
10
4 EMT6 tumour cells injected i.v. and the presence of lung
tumours in the recipient animals was assessed 10 days later. As can
be seen in Figure 3C, animals reconstituted with splenocytes
depleted of CD8
þ T cells were unable to transfer tumour growth
control to SCID mice; in contrast, splenocytes depleted of CD4
þ
cells were able to provide tumour growth control. In a
complementary experiment SCID mice were reconstituted
with CD8
þ T cells isolated from naı ¨ve BALB/cJ mice
(7 10
6cellsmouse
 1). Two days after the adoptive transfer of
the purified CD8
þ T cells the recipient mice were inoculated
subcutaneously with lung tumours and treated with PDT as above.
The presence of lung tumours was assessed 10 days later. SCID
mice receiving CD8
þ T cells had an average of 15.13711.65
tumours/lung (n¼9), which was significantly less than the average
number of lung tumours present in SCID mice that were
not reconstituted (114.6710.75tumours/lung, n¼5; Po0.0001).
These experiments suggest that control of distant disease following
PDT is mediated by CD8
þ T cells and may be CD4
þ T cell
independent.
To demonstrate further that control of distant disease by PDT
was independent of CD4
þ T cells, we examined the efficacy of PDT
in mice lacking CD40. CD4
þ T cells provide help via secretion of
cytokines and CD40/CD40L interactions with dendritic cells (DCs)
(Bennett et al, 1998; Ridge et al, 1998; Schoenberger et al, 1998).
The control of EMT6 lung tumour growth following PDT treatment
of s.c. EMT6 tumours of CD40
-/- mice was not significantly
different from that observed following treatment of s.c. EMT6
tumours in BALB/cJ mice (Figure 3D). These results support the
conclusion that PDT control of tumour growth outside the
treatment field is independent of CD4
þ T cells.
Local PDT treatment leads to increased infiltration of
tumours outside the treatment field by CD8
þ T cells
The ability of local PDT treatment to enhance CD8
þ T-cell control
of tumours present outside the treatment field suggests that these
cells exhibit increased infiltration into the untreated tumours
present outside the treatment field. To test this hypothesis, the
degree of T-cell infiltrate into the untreated tumours of mice
bearing two s.c. tumours was assessed. The left tumour of mice
bearing EMT6 tumours on each shoulder was surgically removed
(SR) or treated with PDT (PDT). At various time points following
treatment the right tumours were removed and examined by flow
cytometry for the presence of infiltrating T cells, which were
defined as CD45
þ, CD3
þ, and either CD4
þ or CD8
þ. The results
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Figure 2 Control of distant tumours by PDT is dependent upon the
presence of adaptive immune cells. S.c. tumours present on BALB/cJ or
SCID mice bearing s.c. and lung tumours were treated with PDT (BALB/cJ,
n¼16; SCID, n¼18). The average number of lung tumours was
determined as described in Materials and Methods; error bars represent
s.e.m. Significance was calculated by Student’s t-test.
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sare shown in Figure 4 and are presented as the total number of
CD45
þ, CD3
þ, CD4
þ or CD8
þ cells present per gram of tumour
tissue. The number of either CD4
þ or CD8
þ T cells present in
untreated right tumour did not change when the left tumour was
surgically removed. There was a significant increase in the number
of CD8
þ T cells present in the untreated right tumour when the
left tumour was treated with PDT (Po0.01 5 days post-treatment
as compared to SR), which was accompanied by a slight decrease
in the number of CD4
þ T cells. Thus local PDT treatment or EMT6
tumours leads to enhanced infiltration of untreated EMT6 tumours
by CD8
þ T cells.
In some mice, right tumour growth was monitored following
PDT treatment of the left tumour. PDT treatment of the left
tumour led to significant delays in the growth of the right s.c.
tumours (data not shown). Castano et al (2003) have reported
similar findings.
Local PDT treatment results in the generation of effective
memory anti-tumour CD8
þ T cells in the absence of CD4
þ
T cells
The results presented in Figure 3 indicate that CD4
þ T cells were
not required for the initial generation of effector CD8
þ T cells
capable of controlling the growth of lung tumours following
distant PDT of s.c. tumours. However, CD4
þ T cells have been
implicated in the generation of effective anti-tumour memory
CD8
þ T cells; therefore we tested whether CD4
þ T cells were
critical to the maintenance of the immune response following PDT.
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Figure 3 Control of distant disease by PDT is mediated by CD8
þ T cells. (A) BALB/cJ mice were treated with isotype control, anti-CD4 or anti-CD8
monoclonal antibodies. Antibody treated animals were bled and the extent of the depletion was confirmed by flow cytometry. Representative dot plots are
shown of samples collected on day 3 and day 10. (B) BALB/cJ mice were treated with isotype control (n¼11), anti-CD4 (n¼11), anti-CD8 (n¼10), or a
combination of anti-CD4 and anti-CD8 antibodies (n¼11) before inoculation with EMT6 tumour cells. S.c. EMT6 tumours were treated with Photofrin-
PDT (135Jcm
 2 given at 75mWcm
 2) and 10 days post-PDT the average number of lung tumours was determined. (C) Splenocytes were harvested from
mice depleted of immune cells as in (B) 3 days after PDT treatment of s.c. tumours and adoptively transferred into SCID mice (10
7cellsmouse
 1). Recipient
animals were challenged with 10
4 EMT6 tumour cells 2 days post-transfer; the presence of lung tumours was assessed 10 days after tumour challenge. (D)
S.c. EMT6 tumours of BALB/cJ (filled bars) or CD40
-/- (open bars) mice bearing s.c. and lung tumours were treated with Photofrin-PDT. Ten days post-PDT
the average number of lung tumours was determined as described in Materials and Methods. Each group contains a minimum of five mice. Error bars
represent s.e.m. in all figures; significance was calculated by Student’s t-test.
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sSCID mice were reconstituted with purified naive CD8
þ T cells
(Figure 5A). Recipient mice were inoculated with s.c. EMT6
tumour cells 3 days after the adoptive transfer of purified CD8
þ
T cells. The resulting tumours were treated with PDT and the mice
were rested for a minimum of 40 days. The rested mice were
challenged by intravenous injection with EMT6 tumour cells.
Lungs were harvested from the mice 10 days post-challenge and
the number of lung tumours present was determined. The
transferred CD8
þ cells were able to prevent lung tumour growth
in recipient SCID mice in the absence of CD4
þ T cells 40 days after
PDT (Figure 5B), suggesting that CD4
þ T cells were not required
for the generation of effective memory CD8
þ T cells.
NK cells modulate the control of distant tumour growth by
local PDT treatment
NK cells can mediate CD8
þ T cell responses in the absence of
CD4
þ T cells (Adam et al, 2005; Combe et al, 2005). PDT enhances
NK activity (Korbelik and Dougherty, 1999) and NK cells have
been shown to have an indirect effect on the control of tumour
growth by PDT (Hendrzak-Henion et al, 1999). To assess whether
NK cells contribute to the control of distant tumours by PDT, SCID
mice were depleted of NK cells using TM-b1, a monoclonal
antibody specific for the IL-2 receptor b chain (IL-2Rb), which has
been shown to deplete effectively NK cells (Tanaka et al, 1993).
Mice were injected both subcutaneously and i.v. with EMT6
tumour cells so that s.c. and lung tumours were established. S.c.
P<0.01
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Figure 4 Increased CD8
þ T-cell infiltrate into distant EMT6 tumours
following PDT. The left tumour of mice bearing a tumour on each shoulder
was treated with PDT or removed surgically (SR); at various time post-
treatment the right untreated tumours were removed and examined by
flow cytometry for the presence of CD45
þ, CD3
þ, CD4
þ cells (circles)
or CD45
þ, CD3
þ, CD8
þ cells (squares) as described previously (Gollnick
et al, 1997). Results are presented as the number of cells per mg of tumour
tissue. Open symbols represent the infiltrate present in untreated tumours
when the left tumour was removed surgically; closed symbols represent the
infiltrate present in right tumours following treatment of the left tumour
with PDT. Tumours from a minimum of three animals were examined from
each group. Error bars represent s.e.m.; significance was calculated by
Student’s t-test.
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Figure 5 Enhancement of memory CD8
þ T cells by PDT is independent of CD4
þ T cells. Spleen cells were isolated from naı ¨ve BALB/cJ mice and
CD8
þ or CD 4
þ T cells were enriched by negative selection as described in Materials and Methods. (A) An aliquot of the enriched population was
subjected to flow cytometry to assess purity. A representative dot plot from the starting population (Control), the enriched CD8
þ T-cell population and a
recipient mouse after tumour challenge (day 40) is shown. (B) The enriched CD8
þ T cell or combined CD8
þ and CD4
þ T cell populations was adoptively
transferred into SCID mice (10
7mouse
 1). Recipient mice were inoculated with EMT6 cells and the resulting tumours were treated with Photofrin-PDT.
Mice cured of tumours were challenged 440 days post-treatment by i.v. injection of EMT6 cells; 10 days following challenge lungs were examined for the
presence of tumours The average number of lung tumours was determined as described in Materials and Methods; error bars represent s.e.m. Significance
was calculated by Student’s t-test.
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stumours were treated with PDT in the usual manner. The number
of lung tumours per mouse 10 days after PDT of the s.c. tumour of
SCID mice bearing s.c. and lung tumours significantly increased in
the absence of NK cells (Figure 6A; Po0.0007), suggesting that NK
cells provide partial control of EMT6 tumours in the absence of T
cells. To determine whether NK cells contribute to the CD4
þ
independent ability of CD8
þ T cells to inhibit the growth of
tumours outside the treatment field, 5 days following NK cell
depletion, purified naı ¨ve CD8
þ T cells were adoptively transferred
into the NK-depleted mice or control mice. In the absence of NK
cells, recipient mice treated with PDT were unable to control lung
tumour growth even in the presence of CD8
þ T cells (Figure 6A)
and exhibited a significant increase in tumour number
(Po0.0001). Because activated CD8
þ T cells express IL-2Rb it is
possible that depletion of NK cells with TMb1 results in depletion
of the adoptively transferred CD8
þ T cells. However, as shown in
Figure 6B, treatment with TMb1 1 week before adoptive transfer of
purified CD8
þ T cells had no effect on CD8
þ T cell presence. To
confirm the results obtained by depletion of NK cells with TMb1,
NK cell depletion was also carried out by administration of rabbit
anti-asialo GM1 (Figure 6C) and similar results were obtained.
These studies suggest that NK cells play a role in the control of
EMT6 tumours present outside the treatment field and that NK
cells are needed for CD8
þ T-cell control of tumours outside the
treatment field.
DISCUSSION
The results presented here represent the first demonstration of
CD8
þ T cell-dependent control of tumours growing outside the
treatment field following PDT; other studies showing inhibition of
tumour growth outside the PDT treatment field have not discerned
the effector cell type required for control of distant tumours
(Gomer et al, 1987; Blank et al, 2001; Castano et al, 2003). We also
demonstrate that PDT results in increased CD8
þ T-cell infiltration
into distant untreated tumours and that control of distant tumours
is tumour specific. Furthermore, our studies suggest that the
control of distant EMT6 tumours is independent of CD4
þ T cells,
but dependent upon NK cells.
Several studies have shown that NK cells can provide help in the
establishment of primary and memory CD8
þ T cell responses. In a
study by Adam et al (2005) the need for CD4
þ T helper cells in
development of long-term CD8
þ T-cell memory against A20
lymphoma could be bypassed by NK-DC interaction. Interferon
(IFN)-g produced by NK cells was necessary for activation of
endogenous DCs and subsequent IL-12 production by the DCs,
which led to induction of CTLs. Mocikat et al (2003) also
demonstrated that NK cells prime DCs to stimulate protective
anti-tumour CD8
þ T cells through secretion of IFN-g. Combe et al
(2005) showed that NK cells mediate CD8
þ T-cell immunity
against Toxoplasma gondii in CD4
þ T-cell deficient mice in an
IL-12-dependent fashion and that depletion of NK cells in mice
lacking CD4T cells led to poor CD8
þ T-cell immunity. The study
further showed that NK responses were upregulated in CD4-
deficient mice. Hendrzak-Henion et al (1999) showed that
depletion of NK cells significantly reduced PDT efficacy against
EMT6 tumours and suggested that the NK effects were indirect as
they were unable to demonstrate direct killing of EMT6 tumour
cells by NK cells. These findings, in combination with our present
results, suggest that PDT-induced anti-tumour CD8
þ T-cell
immunity may be a result of activation of DCs by NK cells.
Although primary CD8
þ T-cell responses have been shown to
be generated in the absence of CD4
þ T cells, CD4
þ T cells appear
to be required for the generation of effective anti-tumour memory
CD8
þ T cells in many systems (Belz et al, 2002; Janssen et al, 2003;
Shedlock and Shen, 2003; Sun and Bevan, 2003). The dependence
upon CD4
þ T cells for the establishment of competent memory
CD8
þ T cells varies with the experimental system (Marzo et al,
2004; Wang et al, 2004; Castellino and Germain, 2006). In our
study, effective anti-tumour memory CD8
þ T-cell responses were
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Figure 6 NK cells contribute to control of distant tumours by local PDT.
(A) SCID mice were treated with TMb1 to deplete NK cells as described in
Materials and Methods. Five days after TMb1 administration, NK-depleted
and isotype-treated mice were injected intravenously with PBS or CD8
þ T
cells purified from naı ¨ve BALB/cJ mice, followed 2 days later by inoculation
of EMT6 tumour cells as described in Materials and Methods. S.c. EMT6
tumours were treated with PDT (135Jcm
 2 given at 75mWcm
 2) and the
average number of lung tumours per mouse was determined as described;
error bars represent s.e.m. Open bars represent animals treated with TMb1;
filled bars represent animals treated with isotype control antibodies. Each
group contained a minimum of five mice per group. Significance was
calculated by Student’s t-test. *Po0.0007, when the number of lung
tumours per mouse treated with TMb1 was compared to the number of
lung tumours present per mouse treated with isotype control antibody.
#Po0.0001, when the number of lung tumours per mouse with CD8
þ
T cells and treated with isotype control antibodies was compared to the
number of lung tumours per mouse treated with isotype control antibodies.
(B) Spleen cells were harvested from CD8
þ recipient mice treated with
either TMb1 or isotype control antibodies at the time of lung tumour
assessment. Cells were stained with antibodies specific for CD3, CD8 and
CD49; flow cytometry analysis was performed and cells were gated based
on CD3 expression. Representative single colour histograms are shown for
cells that were CD3
þ (left panel) or CD3
- (right panel) and expressed
either CD8 or CD49 respectively. Filled histograms indicate cells isolated
from non-depleted mice stained with isotype control antibodies for anti-
CD3 or anti-CD49; open histograms with dashed lines indicate cells isolated
from NK depleted mice; open histograms with solid lines indicate cells
isolated from non-depleted, isotype treated mice. (C) SCID mice were
treated with anti-asialo-GM1 to deplete NK cells as described. Depleted and
control mice were inoculated with EMT6 tumours as described in Materials
and Methods. S.c. EMT6 tumours were treated with PDT (135Jcm
 2 given
at 75mWcm
 2) and the average number of lung tumours per mouse was
determined as described; error bars represent s.e.m. Open bars represent
animals treated with anti-asialo-GM1; filled bars represent animals treated
with isotype control antibodies. Each group contained a minimum of five
mice per group. Significance was calculated by Student’s t-test. *Po0.032,
when the number of lung tumours per mouse treated with anti-asialo-GM1
was compared to the number of lung tumours present per mouse treated
with isotype control antibody.
#Po0.0001, when the number of lung
tumours per mouse with CD8
þ T cells and treated with isotype control
antibodies was compared to the number of lung tumours per mouse
treated with isotype control antibodies.
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sobserved in mice lacking CD4
þ cells (Figure 5). These results are
supported by a study by Korbelik and Dougherty (1999), in which
depletion of CD8
þ T cells substantially impaired the ability of PDT
to suppress EMT6 tumour growth long-term while depletion of
CD4
þ T cells had a minimal effect. However, it is possible that the
transferred naı ¨ve CD8
þ T-cell population used to study the
memory response (Figure 5), which was 495% pure, contained
sufficient CD4
þ cells to provide help for the maintenance of the
memory CD8
þ T-cell population.
The ability of local PDT treatment of tumours to enhance the
formation of memory CD8
þ T cells in the absence of CD4
þ T cells
is in agreement with studies showing that DC stimulated in vitro
with CD40 cross-linking antibodies (Ridge et al, 1998; Ribas et al,
2001) or toll-like receptor (TLR) ligands (Bullock and Yagita, 2005;
Shi and Ziang, 2006) and injected into mice could lead to the
formation of memory CD8
þ T cells. However, our findings
contrast with recent findings in viral (Belz et al, 2002; Janssen et al,
2003; Shedlock and Shen, 2003) and bacterial (Sun and Bevan,
2003) systems in which generation of memory CD8
þ T cells was
found to be dependent upon the presence of CD4
þ T cells. One
potential explanation for the discrepancy lies in the maintenance
of the memory CD8
þ T cells. Bevan and colleagues have shown
that although memory CD8
þ T cells could be generated in the
absence of CD4
þ T cells, their numbers and the functionality of
the memory cells diminished over time (Sun and Bevan, 2003; Sun
et al, 2004) and that diminished function was apparent 30 days
post-activation (Sun et al, 2004). Our studies examining CD8
þ T
cell function 40 days post-activation did not reveal a deficiency,
however; it is possible that CD8
þ T-cell function could be
diminished at later time points.
Depletion of CD4
þ cells by treatment with anti-CD4 antibodies
will also result in depletion of T helper cells and regulatory T cells,
which are CD4
þ and have been shown to suppress anti-tumour
immunity (reviewed in Zou, 2006). Thus it is possible that our
results showing control of distant disease following depletion of
CD4
þ cells or transfer of purified CD8
þ T cells is a result of
enhanced CD8
þ T-cell activity in the absence of suppression.
However, depletion of CD4
þ cells in immuno-competent mice
does not significantly enhance the ability of CD8
þ cells to control
distant disease (Figure 1B) and the ability of CD8
þ cells to control
distant tumour growth is not significantly affected by the presence
of CD4
þ T cells when purified cell populations are transferred to
immunocompromised mice (Figure 5B).
Establishment of CD8
þ T-cell memory responses in the absence
of CD4
þ T cells also appears to be related to the extent and nature
of the inflammatory response generated at the time of antigen
exposure, which can affect the activation status of antigen-
presenting cells (Matzinger, 1994; Kaisho and Akira, 2003; Bullock
and Yagita, 2005). The activation status of antigen-presenting cells,
particularly that of DCs is critical to their ability to stimulate fully
the generation of CD8 memory T cells (Ridge et al, 1998; van
Mierlo et al, 2004). DC activation or licensing by CD4
þ T cells can
be replaced by DC recognition of exogenous (Janeway and
Medzhitov, 2002) or endogenous (Matzinger, 2002) TLR ligands
or danger signals. Endogenous danger signals include release of
stress proteins and products of dead cells including heat shock
proteins (HSP) and uric acid (Moseley, 2000; Gallucci and
Matzinger, 2001; Shi et al, 2003). PDT causes systemic inflamma-
tion and direct tumour cell death (Dougherty et al, 1998; Castano
et al, 2006) that is accompanied by cell surface expression of
HSP70 (Korbelik et al, 2005). Thus it is possible that local PDT
treatment of tumours leads to release of factors capable of
bypassing the need for CD4
þ T cells in the activation of DCs. In
support of this hypothesis, we have recently shown that PDT
treatment of EMT6 and Colon26 tumours enhances maturation
and activation of DCs and that DCs isolated from PDT treated mice
are able to stimulate T-cell effector functions (Gollnick et al, 2006).
Diverse PDT regimens and photosensitisers can lead to differing
levels of inflammation (Henderson et al, 2004) and it has been
suggested that the development of an adaptive immune response is
dependent upon the degree of the inflammatory response (Akira
et al, 2001; Lanzavecchia and Sallusto, 2001; Nestle et al, 2001;
Schnare et al, 2001; Matzinger, 2002). The regimen-dependent
induction of inflammatory responses following PDT could also
account for the failure of other groups to detect an effect of Foscan
(meta-tetrahydroxyphenylchlorin)-PDT of orthotopic rat liver
tumours on liver tumours present outside the treatment field
(van Duijnhoven et al, 2003). In addition, NK cell activation of DCs
in anti-tumour immunity appears to depend upon tumour
expression of NKG2D ligands (Adam et al, 2005), or expression
of costimulatory molecules such as CD70, CD80 or CD86 (Kelly
et al, 2002); EMT6 tumours are immunogenic (Siemann et al, 1981)
respond well to PDT (Korbelik and Dougherty, 1999) and may be
more susceptible to immune-mediated control. PDT is likely to be
less effective at stimulating systemic anti-tumour immune
responses against less immunogenic tumours such as those used
in other PDT studies of systemic immunity (van Duijnhoven et al,
2003). Thus PDT control of distant disease is likely to be regimen
and tumour-dependent.
The perceived lack of systemic effectiveness of PDT has limited
its usage for the treatment of advanced disseminated disease. The
findings presented in this study suggest that it may be possible to
devise clinical PDT treatment regimens capable of enhancing
systemic anti-tumour immune responses. Most of the therapies
currently used to treat disseminated disease, including chemother-
apy and radiation, have negative effects on the host immune
response. The availability of a tumour treatment capable of
eliminating the primary tumour while simultaneously stimulating
anti-tumour immunity would be significant.
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